Skip to content
Search

Latest Stories

Dr Reddy's enters UK consumer health market, launches allergy medication Histallay

Dr Reddy's enters UK consumer health market, launches allergy medication Histallay

People with hay fever can now get direct access to the product through pharmacies and supermarkets in the UK.  

Indian multinational pharmaceutical company, Dr. Reddy's Laboratories has made its entry into the UK consumer health market with the launch of an over-the-counter allergy medication.


Histallay (Fexofenadine Hydrochloride 120 mg tablets) is the company’s first general sale list (GSL) product introduced in the UK market.

Previously classified as a Prescription Only Medicine (POM), Dr. Reddy's Fexofenadine 120 mg is now available without prescription, under the brand name ‘Histallay’.

This allows people with allergic seasonal rhinitis (hay fever) to get direct access to the product via retail outlets such as pharmacies and supermarkets in the UK.

The Indian company said it is already one of the largest producers of Fexofenadine Hydrochloride ( the active pharmaceutical ingredient in Histallay), which is the most dispensed antihistamine in the UK.

“Entering consumer healthcare is a logical step for us and true to our purpose of offering more choices for customers and patients.

“Our expertise in the allergy segment has already allowed us to become a leader in the UK’s prescription fexofenadine market.

“By making Histallay available over the counter, we enable allergy sufferers to get faster access to treatment and better control over their symptoms since early treatment is key,” the company writes on its website.

Screenshot 2024 01 25 164551

What is Hay fever?

Hay fever, also called allergic rhinitis, is an allergic reaction commonly triggered by pollen, house dust mites, mould spores, and pet dander.

According to NHS, cases are higher between late March and September, when the pollen count is at its highest.

Hay fever causes cold-like symptoms, including a runny or blocked nose, sneezing and coughing, itchy eyes and throat, loss of smell, headache, earache, and tiredness.

For people with asthma, their symptoms may get worse when they have hay fever. They may experience a tight feeling in the chest, shortness of breath, wheezing, and cough.

While a cold usually goes away after 1 to 2 weeks, hay fever can last for weeks or months, the health service stated.

How to treat hay fever

Unfortunately, there's currently no cure for hay fever, but treatment can help relieve symptoms at least to a certain extent for most people.

Hay fever treatments include antihistamines (for preventing an allergic reaction) and corticosteroids or steroids (for reducing inflammation and swelling).

If you have hay fever, you can speak to your pharmacist, who can give you advice and suggest the best treatments.

The NHS advised people to see a doctor if their symptoms do not improve after taking medicines from the pharmacy and are getting worse.

More For You

Youth vaping : project to examine health impacts on children

Youth vaping : project to examine health impacts on children

Youth vaping: £62M research project to examine health impacts on children

The UK government has announced a £62 million research project to investigate the long-term health effects of vaping on young people, alongside wider influences on adolescent health and wellbeing.

While vaping is considered less harmful than smoking and can aid adult smokers in quitting, youth vaping has skyrocketed in recent years, with a quarter of 11 to 15-year-olds having tried it, the Department of Health and Social Care (DHSC) noted in a release.

Keep ReadingShow less
David Thomas Steps In as NPA’s New Wales Representative
Five NPA members are contesting for the remaining position in England (gettyimages)

NPA board update: David Thomas succeeds Raj Aggarwal OBE

Five NPA members are contesting for the remaining position in England

David Thomas, owner of LT Chemists in Newport, will replace Raj Aggarwal OBE as the next National Pharmacy Association (NPA) board member for Wales, following an uncontested election this month.

Following the conclusion of a nomination process last week, Baldev Bange, Aisling O’Brien, Sehar Shahid, and Sanjay Ganvir have been re-elected to the Board, representing areas of England and Scotland, according to a statement from NPA.

Keep ReadingShow less
Public Policy Projects calls for better use of community pharmacy skill mix to improve medicines adherence
Non-adherence to medicines remains a critical issue, with an estimated 30 to 50 per cent of medicines for long-term conditions not taken as prescribed. (gettyimages)

Leverage pharmacy skill mix to improve medicines adherence - report suggests

The report also suggested expanding the community pharmacy contractual framework to enable community pharmacy to deliver medicines reviews

Pharmacy technicians and assistants should be enabled to talk to patients about their medications to improve medicines adherence, a new report has recommended.

The report, How medicines optimisation contributes to population health, published recently by policy institute Public Policy Projects, highlighted that non-adherence to medicines remains a critical issue, with an estimated 30 to 50 per cent of medicines for long-term conditions not taken as prescribed.

Keep ReadingShow less
GHP calls for 10% mandated protected learning time for NHS pharmacists in new campaign
Many pharmacists end up doing ‘unpaid work’ to catch up with the required training (gettyimages)

Increase protected learning time for NHS pharmacists – GHP launches national campaign

Many pharmacists end up doing ‘unpaid work’ to catch up with the required training or completing self-learning in their own time.

The Guild of Healthcare Pharmacists (GHP) has launched a national campaign advocating for pharmacists working in the NHS to have a minimum of 10% of their contracted hours protected for supporting professional activities (SPA).

In a statement published on 7 February 2025, the GHP emphasised that this protected time “should be recognized by employers and embedded in job plans.”

Keep ReadingShow less
Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Pharmacy contract consultation to review medicine margin and reimbursement, says Kinnock

Kinnock confirms that an announcement on the 2025/26 GP contract would be made before April 2025

The 2025/26 pharmacy contract consultation will include a review of the medicine margin and reimbursement arrangements, health and care minister Stephen Kinnock has confirmed.

Kinnock made this statement in response to a written question from Nick Timothy, Conservative MP for West Suffolk, who asked the secretary of state for health and social care, if he will review the reimbursement system for pharmacies and GP practices dispensing medicines.

Keep ReadingShow less